DOI : 10.1055/s-00000094

Zeitschrift für Gastroenterologie

Ausgabe 01 · Volume 58 · Januar 2020 DOI: 10.1055/s-009-45326

Deutsche Arbeitsgemeinschaft zum Studium der Leber (GASL)
36. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber
Mainz, 14.–15.02.2020

Kongresspräsident: Prof. Dr. Peter Galle
Abstracts (HTML) Autorenliste
2.4
Hohmann, N; Haefeli, WE; Mueller, S; Seitz, H; Schröder, F; Teng, H; Moreira, B; Bruckner, T: Clomethiazole improves alcoholic fatty liver in patients admitted to the hospital for alcohol detoxification therapy
2.5
Manka, P; Sydor, S; Helbeck, A; Brandenburg, M; Canbay, A; Kahraman, A; Wedemeyer, H; Bechmann, L: Hepatic steatosis in Crohn's disease: associations with anti-TNFα treatment, dysbiosis, and FGF-19.
2.6
Liebig, S; Stöckmann, N; Geier, A; Rau, M; Schattenberg, J; Bahr, M; Manns, M; Schulze-Osthoff, K; Jaeckel, E; Bantel, H: Diagnostic algorithm to detect NASH and fibrosis in NAFLD patients with low NAFLD fibrosis score or liver stiffness
2.7
Reichert, MC; Schneider, C; Greinert, R; Casper, M; Grünhage, F; Zipprich, A; Lammert, F; Ripoll, C: Isolated bacterial infection without decompensation has no impact on survival of compensated patients
2.8
Ambrosy, L; Boutin, S; Kloeters-Plachky, P; Sauer, P; Bode, K; Rupp, C: Alteration of the gut microbiota in patients with primary sclerosing cholangitis and concomitant dominant strictures
2.9
Zhang, CC; Voitl, R; Kloeters-Plachky, P; Weiss, KH; Sauer, P; Rupp, C: Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis
2.10
Hamesch, K; Schneider, C; Mandorfer, M; Moeller, L; Pereira, V; Pons, M; Reichert, M; Fromme, M; Miravittles, M; Janciauskiene, S; Lammert, F; Genesca, J; Krag, A; Trauner, M; Trautwein, C; Strnad, P: Die Therapie mit Alpha-1-Antitrypsin (AAT) assoziiert bei AAT-Mangel mit besseren Leber-bezogenen Parametern
2.11
Hilscher, M; Weigel, S; Kremer, WM; Ploch, P; Nagel, M; Michel, M; Ahlbrand, CJ; Kaps, L; Nagel, M; Klöckner, R; Weinmann, A; Galle, PR; Labenz, C; Wörns, MA: Non-malignant portal vein thrombosis in liver cirrhosis – predictors of risk and the use of anticoagulation
2.12
Prinz, C: Relapse rates in patients with autoimmune hepatitis after withdrawal of medication.
2.13
Kaps, L; Ahlbrand, CJ; Gadban, R; Kremer, WM; Labenz, C; Nagel, M; Ploch, P; Marquardt, JU; Peter, GR; Schattenberg, JM; Weinmann-Menke, J: Extrakorporale Leberunterstützung mit ADVOS in Patienten mit ACLV und HRS – Erste Ergebnisse einer Single Center Studie
2.14
Ohm, D; Rödel, J; Will, U; Stallmach, A; Bruns, T; Reuken, P: Antibiotische Therapie von Leberabszessen: Enterokokken sind eine häufige Ursache für ein Therapieversagen
2.15
Schneider, AT; Koppe, C; Castoldi, M; Loosen, SH; Kather, JN; Trautwein, C; Vucur, M; Lüdde, T: RIPK1 and MLKL in hepatocytes do not mediate Concanavalin A (ConA)-mediated liver toxicity
2.16
Praktiknjo, M; Monteiro, S; Grandt, J; Kimer, N; Madsen, JL; Werge, MP; Illiam, PW; Brol, M; Turco, L; Schierwagen, R; Chang, J; Klein, S; Jansen, C; Uschner, F; Welsch, C; Moreau, R; Schepis, F; Bendtsen, F; Gluud, LL; Møller, S; Trebicka, J: Systemic inflammation is associated with hyperdynamic circulation and predicts acute-on-chronic liver failure
2.17
Seifert, LL; Schindler, P; Köhler, M; Riegel, A; Masthoff, M; Wildgruber, M; Heinzow, H: Predictive parameters and effectiveness of TIPS reduction in treatment of hepatic encephalopathy after TIPS
2.18
Christidis, G; Lammert, F: Endokrine Störungen bei Leberzirrhose: häufig, aber wenig beachtet
2.19
Rössle, M; Michael, S; Dominik, B; Robert, T: Fibroseprogredienz bei Patienten mit Budd-Chiari Syndrom
2.20
Labenz, C; Nagel, M; Huber, Y; Marquardt, JU; Galle, PR; Schattenberg, JM; Wörns, MA: Outcome prediction of covert hepatic encephalopathy in liver cirrhosis: comparison of four testing strategies
2.21
Dröge, C; Brinkert, F; Grabhorn, E; Briem-Richter, A; Stepanow, S; Köhrer, K; Herebian, D; Häussinger, D; Keitel, V: Whole exome sequencing analysis revealed an inherited AKR1D1 defect in twins with infantile intrahepatic cholestasis
2.22
Nagel, M; Labenz, C; Nguyen-Tat, M; Cabezas Wallscheid, N; Czauderna, C; Schattenberg, J; Wörns, MA; Galle, PR; Marquardt, J: Vitamin A deficiency is associated with disease severity in patients with liver cirrhosis
2.23
Hahn, F; Müller, L; Düber, C; Weinmann, A; Kloeckner, R; Mähringer-Kunz, A: Extending the reach of the ALBI score for primary hepatic malignancies: Does ALBI work for cholangiocarcinoma?
2.24
Abu-Omar, J; Faron, A; Chang, J; Böhling, N; Sprinkart, AM; Meyer, C; Strassburg, C; Jansen, C; Trebicka, J; Luetkens, J; Praktiknjo, M: Low muscle mass and large portosystemic shunt in “one-stop shop” CT exponentially increases risk for HE and mortality
2.25
Manka, P; Baba, H; Wedemeyer, H; Kahraman, A: Slow progressive very late-onset LAL-D: the importance of liver biopsy
2.26
Kaps, L; Grambihler, A; Yemane, B; Nagel, M; Labenz, C; Ploch, P; Kremer, M; Michel, M; Ahlbrand, CJ; Galle, PR; Wörns, MA; Schattenberg, JM: Symptom burden and treatment response in patients with primary biliary cholangitis (PBC)
2.27
Vogel, A; Häussinger, D; Bode, J: Retrospektive Analyse des Therapieerfolgs von TIPS Anlagen und Identifikation prognostischer Parameter hierfür
2.28
Kremer, WM; Ismaili, E; Ploch, P; Ahlbrand, CJ; Hilscher, M; Kaps, L; Michel, M; Galle, PR; Wörns, MA; Sprinzl, M; Nagel, M; Labenz, C: Epidemiologie und Auswirkungen bakterieller Infektionen bei stationären Patienten mit Leberzirrhose
2.29
Zizer, E; Braun, A; Seufferlein, T; Backhus, J: Wertigkeit der Minilaparoskopie bei der makroskopischen Beurteilung der Lebersteatose
2.30
Goebel, P; Forsting, C; Knipper, P; Manekeller, S; Nattermann, J; Kalff, J; Wahl, G; Strassburg, C; Lutz, P: Dental health needs assessment and treatment in patients awaiting liver transplant
2.31
Schmid, S; Maier-Stocker, C; Vogg, J; Gülow, K; Müller-Schilling, M: Correlation of Liver Perfusion with Outcome of Patients with Severe Liver Disease – A Prospective Cohort Study